Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments fail, though it can create a cost burden, and how beyond updated guidelines, ...
Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...
A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback